Fosun Pharma acquires exclusive rights to ReNeuron cell therapies for Chinese market

ReNeuron, a UK-based stem cell research company, announced that it has signed an exclusive license agreement with Fosun Pharma, a Chinese listed pharmaceutical company, for the development, manufacture and commercialisation of ReNeuron ' s CTX and hRPC cell therapy programmes in China. What ’s it about
Source: mobihealthnews - Category: Information Technology Source Type: news